Monitoring of anthracycline-induced cardiotoxicity

Annals of Pharmacotherapy

Volumn 42, Issue 1, 2008, Pages 99-104

  Jannazzo, Abigail ^a,b   Hoffman, Janet ^a   Lutz, Mark ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Anthracycline; Cardiotoxicity; Detection; Monitoring; Prevention

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; RAZOXANE;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG COST; DRUG MONITORING; ECHOCARDIOGRAPHY; FOLLOW UP; HEART FUNCTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; DRUG MONITORING; ECHOCARDIOGRAPHY; HEART DISEASES; HUMANS; PRACTICE GUIDELINES AS TOPIC; RADIONUCLIDE ANGIOGRAPHY; RISK ASSESSMENT;

EID: 38049007892     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K359     Document Type: Review

References (26)

1. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7. DOI 10.1001/jama.266.12.1672
2. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005;131:561-78. DOI 10.1111/j.1365-2141.2005.05759.x
3. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
4. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006;33(3 suppl 8):S2-7. DOI 10.1053/j.seminoncol.2006.04.020
5. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999;25:237-47. DOI 10.1053/ctrv.1999.0128
6. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68. DOI 10.1016/S1040-8428(97)10007-5
7. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14. DOI 10.1002/1097-0142(197308)32:2〈302::AID-CNCR2820320205〉3.0.CO;2-2
8. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006;42:3191-8. DOI 10.1016/j.ejca.2006.08.005
9. Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 2001;28:2-7.
10. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-903. DOI 10.1200/JCO.2002.04.178
11. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005;112:154-253. DOI 10.1161/CIRCULATIONAHA.105.167586
12. Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging. 2003. www.acc.org/ qualityandscience/clinical/guidelines/radio/index.pdf (accessed 2007 May 26).
13. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography. 2003. www.acc.org/qualityandscience/clinical/guidelines/echo/index.pdf (accessed 2007 May 26).
14. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the Childrens Cancer Study Group. Pediatrics 1992;89:942-9.
15. Lipshultz SE, Sanders SP, Colan SD, Goorin AM, Sallan SE, Krischer JP. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994;93:433-7.
16. van Dalen EC, van den Brug M, Caron HB, Kremer LC. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer 2006;42:3199-205. DOI 10.1016/j.ejca.2006.08.002
17. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002;86:1697-700. DOI 10.1038/sj.bjc.6600346
18. Belham M, Kruger A, Mepham S, Faganello G, Pritchard C. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007;9:409-14. DOI 10.1016/j.ejheart.2006.09.2007
19. Meinardi MT, van Veldhuisen JA, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001;19:2746-53.
20. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709. DOI 10.1093/annonc/mdf132
21. Pichon MF, Cvitkovic F, Hacene K, et al. Drug-induced cardiotoxicity studied by longitudinal B-type natiuretic peptide assays and radionuclide ventriculography. In Vivo 2005;19:567-76.
22. Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004;42:220-4. DOI 10.1002/pbc.10368
23. Kremer LC, Bastiaansen BA, Offringa M, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002;38:686-9. DOI 10.1016/S0959-8049(01)00431- 2
24. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22. DOI 10.1016/S0735-1097(00)00748-8
25. Porea TJ, Dreyer ZE, Bricker T, Mahoney DH. Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol 2001;23:420-3. DOI 10.1097/00043426-200110000-00006
26. Sabel MS, Levine EG, Hurd T, et al. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-adjuvant therapy? Am J Clin Oncol 2001;24:425-8. DOI 10.1097/00000421-200108000-00027